Table 1. PD-L1 expression by immunohistochemistry in different studies.

Reference	Tumor type	Drug	IHC Ab	Cell location	Cut-off (%)	n (PD-L1)	PD-L1+ pt (%)	ORR (%) PD-L1+	ORR (%) PD-L1-
Topalian et al.30	Solid	Nivolumab	5H1	Tumor cells (mb)	5	42	59.5	36	0
D'Incecco et al.59	Lung	Gefitinib/Erlotinib	58810	Tumor cells	5	98	53.1	61.2	34.8
Powles et al.60	Bladder	MPDL3280A	SP142	Tumor cells	5	205	10.73	28.6	25.9
				IC			26.8	43.3	11.1
Herbst et al.61	Lung	MPDL3280A	SP142	Tumor cells (mb and cyto)	5	53	24	33	22
				IC			26	46.1	18.2
Grosso et al.62	Melanoma	Nivolumab	28-8	Tumor cells (mb)	5	38	45	44	17
Brahmer et al.58	Solid	Nivolumab	5H1	Tumor cells (mb)	5	9	44.4	75	0
Garon et al.63	Lung	Pembrolizumab	22C3	Tumor cells (mb)	50	824	23.2	42.3	14.8
Konishi et al.64	Lung	–	MIH1	Tumor cells (mb and cyto)	1	52	27.2	–	–
Dong et al.44	Lung	–	5H1	Tumor cells (mb and cyto)	10	21	95	–	–
Hamanishi et al.50	Ovarian	–	27A2	Tumor cells	Moderate intensity	70	68.6	80.2	52.6
Taube et al.65	Solid	Nivolumab	5H1	Tumor cells (mb)	5	41	56	39	6
				IC			56	35	11

Ab, antibody; cyto, cytoplasm; IC, immune cells; mb, membrane; ORR, objective response rate; pt, patient.